Reckitt CEO's $17B Predicament Post author:Sam Post published:December 26, 2017 Post category:BioPharma 2018 is the year for Rakesh Kapoor to show he’s worth it. Source: BioSpace You Might Also Like Amgen-Backed Immatics Lands $58 Million To Develop T-Cell Receptor Based Immunotherapies October 3, 2017 Novartis Buys Rare Drug Voucher for $130M From Ultragenyx December 17, 2017 <b>Ramaswamy</b> Launches Another New Biotech to Work on Phase III-Ready Drug From Merck & Co. June 5, 2017
Amgen-Backed Immatics Lands $58 Million To Develop T-Cell Receptor Based Immunotherapies October 3, 2017
<b>Ramaswamy</b> Launches Another New Biotech to Work on Phase III-Ready Drug From Merck & Co. June 5, 2017
